Notwithstanding encouraging clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable difficulty from PBMs. These insurers are typically building barriers to coverage, like steep expense restrictions and approval processes that limit consumer availability. Market suggest that